Presence of membrane and soluble forms of Fas ligand and of matrilysin (MMP-7) activity in normal and abnormal human semen

Human Reproduction

Volumn 20, Issue 10, 2005, Pages 2814-2820

  Riccioli, A ^a   Dal Secco, V ^a   De Cesaris, P ^b   Starace, D ^a   Gandini, L ^a   Lenzi, A ^a   Dondero, F ^a   Padula, F ^a   Filippini, A ^a   Ziparo, Elio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Apoptosis; Fas system; Matrilysin; Spermatozoa

Indexed keywords

FAS LIGAND; MATRILYSIN;

ADULT; APOPTOSIS; ARTICLE; AZOOSPERMIA; ENZYME ACTIVITY; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SEMEN ANALYSIS; SPERMATOZOON DENSITY; SPERMATOZOON MOTILITY; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 27144526595     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dei149     Document Type: Article

References (49)

1. Baragi VM, Fliszar CJ, Conroy MC, Ye QZ, Shipley JM and Welgus HG (1994) Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin. J Biol Chem 269,12692-12697.
2. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A and Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377,630-632.
3. Buchman-Shaked O, Kraiem Z, Gonen Y and Goldman S (2002) Presence of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinase in human sperm. J Androl 23,702-708.
4. D'Alessio A, Riccioli A, Lauretti P, Padula F, Muciaccia B, De Cesaris P, Filippini A, Nagata S and Ziparo E (200 1) Testicular FasL is expressed by sperm cells. Proc Natl Acad Sci USA 98,3316-3321.
5. Denison FC, Grant VE, Calder AA and Kelly RW (1999) Seminal plasma components stimulate interleukin-8 and interleukin-10 release. Mol Hum Reprod 5,220-226.
6. Dhein J, Walczak H, Baumier C, Debatin KM and Krammer PH (1995) Autocrine T-cell suicide mediated by Apo-1/Fas/CD95. Nature 373,438-448.
7. Evans CH, Lee TS and Flugelman AA (1995) Spermine-directed immunosuppression of cervical carcinoma cell sensitivity to a majority of lymphokine-activated killer lymphocyte cytotoxicity. Nat Immunol 14,157-163.
8. Fiedler P, Schaetzlein CE and Eibel H (1998) Constitutive expression of FasL in thyrocytes. Science 279,2015a.
9. Filippini A, Riccioli A, Padula F, Lauretti P, D'Alessio A, De Cesaris P, Gandini L, Lenzi A and Ziparo E (2001) Control and impairment of immune privilege in the testis and in semen. Hum Reprod Update 7,444-449.
10. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ and Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81,935-946.
11. Francavilla S, D'Abrizio P, Rucci N, Silvano G, Properzi G, Straface E, Cordeschi G, Necozione S, Gnessi L, Arizzi M et al. (2000) Fas and Fas ligand expression in fetal and adult human testis with normal or deranged spermatogenesis. J Clin Endocrinol Metab 85,2692-2700.
12. Fujisawa M and Ishikawa T (2003) Soluble forms of Fas and Fas ligand concentrations in the seminal plasma of infertile men with varicocele. J Urol 170,2363-2365.
13. Gandini L, Lombardo F, Paoli D, Caponecchia L, Familiari G, Verlengia C, Dondero F and Lenzi A (2000) Study of apoptotic DNA fragmentation in human spermatozoa. Hum Reprod 15,830-839.
14. Green DR and Ferguson TA (2001) The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2,917-924.
15. Hashimoto K, Kihira Y, Matuo Y and Usui T (1998) Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 160,1872-1876.
16. Hulboy DL, Rudolph LA and Matrisian LM (1997) Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 3,27-45.
17. Kelly RW (1995) Immunosuppressive mechanisms in semen: Implications for contraception. Hum Reprod 10, 1686-1693.
18. Kimmel SG, Ohbatake M, Kushida M, Merguerian P, Clarke ID and Kim PC (2000) Murine xenogeneic immune responses to the human testis: A presumed immune-privileged tissue. Transplantation 69,1075-1084.
19. Knox PG, Milner AE, Green NK, Eliopoulos AG and Young LS (2003) Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol 170,677-685.
20. Lee J, Richburg JH, Younkin SC and Boekelheide K (1997) The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 138,2081-2088.
21. Leeman MF, Curran S and Murray GI (2003) New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201,528-534.
22. Liabakk NB, Lien E, Sundan A, Sunde A, Austgulen R and Espevik T (1993) High concentrations of the soluble p55 tumour necrosis factor receptor in human seminal plasma. Hum Reprod 8,1837-1842.
23. McVicar CM, McClure N, Williamson K, Dalzell LH and Lewis SE (2004) Incidence of Fas positivity and deoxyribonucleic acid double-stranded breaks in human ejaculated sperm. Fertil Steril 81 Suppl 1,767-774.
24. Nagata S (1999) Fas ligand-induced apoptosis. Annu Rev Genet 33,29-55.
25. Nair R and Shaha C (2003) Diethylstilbestrol induces rat spermatogenic cell apoptosis in vivo through increased expression of spermatogenic cell Fas/FasL system. J Biol Chem 278,6470-6481.
26. Nocera M and Chu TM (1993) Transforming growth factor beta as an immunosuppressive protein in human seminal plasma. Am J Reprod Immunol 30,1-8.
27. Powell WC, Fingleton B, Wilson CL, Boothby M and Matrisian LM (1999) The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9,1441-1447.
28. Restifo NP (2000) Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6,493-495.
29. Riccioli A, Salvati L, D'Alessio A, Starace D, Giampietri C, De Cesaris P, Filippini A and Ziparo E (2003) The Fas system in the seminiferous epithelium and its possible extra-testicular role. Andrologia 35,64-70.
30. Rodgers WH, Osteen KG, Matrisian LM, Navre M, Giudice LC and Gorstein F (1993) Expression and localization of matrilysin, a matrix metalloproteinase, in human endometrium during the reproductive cycle. Am J Obstet Gynecol 168,253-260.
31. Rudolph-Owen LA, Hulboy DL, Wilson CL, Mudgett J and Matrisian LM (1997) Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology 138,4902-4911.
32. Saarialho-Kere UK, Crouch EC and Parks WC (1995) Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 105,190-196.
33. Sakkas D, Mariethoz E and St.John JC (1999) Abnormal sperm parameters in humans are indicative of an abortive apoptotic mechanism linked to the Fas-mediated pathway. Exp Cell Res 251,350-355.
34. Sakkas D, Moffatt O, Manicardi GC, Mariethoz E, Tarozzi N and Bizzaro D (2002) Nature of DNA damage in ejaculated human spermatozoa and the possible involvement of apoptosis. Biol Reprod 66,1061-1067.
35. Shen HM, Dai J, Chia SE, Lim A and Ong CN (2002) Detection of apoptotic alterations in sperm in subfertile patients and their correlations with sperm quality. Hum Reprod 17,1266-1273.
36. Somerville RP, Oblander SA and Apte SS (2003) Matrix metalloproteinases: old dogs with new tricks. Genome Biol 4,216.
37. Suda T, Takahashi T, Goldstein P and Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75,1169-1178.
38. Sugihara A, Yamada N, Tsujimura T, Iwasaki T, Yamashita K, Takagi Y, Tsuji M and Terada N (2001) Castration induces apoptosis in the male accessory sex organs of Fas-deficient lpr and Fas ligand-deficient gld mutant mice. In Vivo 15,385-390.
39. Suzuki A, Matsuzawa A and Iguchi T (1996) Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene 13,31-37.
40. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T and Nagata S (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76,969-976.
41. Tanaka M, Suda T, Takahashi T and Nagata S (1995) Expression of the functional soluble form of human Fas ligand in activated lynphocytes. EMBO J 14,1129.
42. Thompson LA, Barratt CL, Bolton AE and Cooke ID (1992) The leukocytic reaction of the human uterine cervix. Am J Reprod Immunol 28,85-89.
43. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA and Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356,314.
44. Werb Z (1997) ECM and cell surface proteolysis: Regulating cellular ecology. Cell 91,439-442.
45. World Health Organization (1992) WHO Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interactions, 3rd edn. Cambridge University Press, Cambridge.
46. World Health Organization (1999) WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction, 4th edn. Cambridge University Press, Cambridge.
47. Wilson CL, Heppner KJ, Rudolph LA and Matrisian LM (1995) The metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue-restricted pattern in the mouse. Mol Biol Cell 6,851-869.
48. Wilson CL, Heppner KJ, Labosky PA, Hogan BL and Matrisian LM (1997) Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94,1402-1407.
49. Zhang J, Jung K, Lein M, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA and Lichtinghagen R (2002) Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines. Prostate 50,38-45.